Abstract：Objective To study the clinical efficacy of Budesonide combined with pulmonary surfactant (PS) in neonates with meconium aspiration syndrome (MAS). Methods A total of 98 neonates with MAS in General Hospital of China Aviation of China Medical University from May 2014 to May 2017 were enrolled and divided into the control group (n = 49) and the treatment group (n = 49) by random number table. The control group was treated with PS dropping into trachea, the treatment group was treated with Budesonide combined with PS dropping into trachea, both were intratracheal drops. The clinical efficacy of the two groups; the PaO2, PaCO2 and TcSaO2 of the two groups at the times of before treatment (0 h), 12 h after treatment, 24 h after treatment and 48 h after treatment; the hospital stays, oxygen exposure time and mechanical ventilation time of the two groups were recorded and compared. The adverse reactions rates of the two groups after treatment were compared. Results The total efficacy rate of the treatment group was 93.88% (46/49), was higher than that of the control group [75.51% (37/49)], the difference was statistically significant (P < 0.05). The PaO2, PaCO2 and TcSaO2 of the two groups at each time poinits after treatment were significantly better than at the times of 0 h (P < 0.05), as the extension of time, the PaO2 and TcSaO2 gradually increased, the PaCO2 gradually reduced, and the PaO2, PaCO2 and TcSaO2 of the treatment group at each time points after treatment were significantly better than that of the control group, the differences were statistically significant (P < 0.01). The hospital stays, oxygen exposure time and mechanical ventilation time of the treatment group were significantly shorter than those of the control group, the differences were statistically significant (P < 0.01). After treatment, the adverse reaction rate of the treatment group was significantly lower than that of the control group, the difference was statistically significant (P < 0.05). Conclusion Budesonide combined with PS in the treatment of neonates with MAS has a good efficacy and low adverse reactions, can reduce the treatment time, improve the oxygenation function, it is worth popularizing in clinical application.
王丽 王秋月▲. 布地奈德联合肺表面活性物质气管内滴入治疗胎粪吸入综合征的临床效果[J]. 中国医药导报, 2018, 15(23): 67-70.
WANG Li WANG Qiuyue▲. Clinical efficacy of intratracheal instillation of Budesonide combined with pulmonary surfactant in the treatment of meconium aspiration syndrome. 中国医药导报, 2018, 15(23): 67-70.
2018, Vol. 15 
京公网安备 11010502046598号